MCID: SML036
MIFTS: 51

Small Intestinal Adenocarcinoma

Categories: Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Small Intestinal Adenocarcinoma

MalaCards integrated aliases for Small Intestinal Adenocarcinoma:

Name: Small Intestinal Adenocarcinoma 53
Adenocarcinoma of the Small Instestine 53 59
Adenocarcinoma of the Small Bowel 53 59
Adenocarcinoma of Small Instestine 53
Adenocarcinoma of Small Intestine 73
Adenocarcinoma of Small Bowel 53
Small Bowel Adenocarcinoma 53

Classifications:



External Ids:

Orphanet 59 ORPHA104075
ICD10 via Orphanet 34 D01.4
UMLS via Orphanet 74 C0278803
UMLS 73 C0278803

Summaries for Small Intestinal Adenocarcinoma

NIH Rare Diseases : 53 Small intestine adenocarcinoma is one type of small bowel cancer, usually occurring in the duodenum or jejunum, that begins in the gland cells. The small intestine is part of the body’s digestive system, which also includes the esophagus, stomach, and large intestine. The exact cause is still unknown, but it may be due to DNA changes in the small intestine adenocarcinoma cells. The symptoms of small bowel tumors are often vague. The most common symptoms are pain in the belly (which may be the first symptom), weight loss, weakness, fatigue and low red blood cell counts (anemia). The treatment and prognosis for small intestine cancer depends on its stage (tumor size and site) and the presence of metastases. For early stage cancer, surgery may be all that is needed. For more advanced cancer chemotherapy or radiation therapy may be required. Please visit the National Cancer Institute website for additional information:Small Intestine Cancer Treatment (PDQ®)–Patient Version

MalaCards based summary : Small Intestinal Adenocarcinoma, also known as adenocarcinoma of the small instestine, is related to adenosquamous carcinoma and adenocarcinoma. An important gene associated with Small Intestinal Adenocarcinoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include small intestine, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Small Intestinal Adenocarcinoma

Diseases related to Small Intestinal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 adenosquamous carcinoma 30.4 EGFR KRAS MUC1
2 adenocarcinoma 29.4 BRAF CTNNB1 EGFR ERBB2 KRAS MUC1
3 colorectal adenocarcinoma 29.3 BRAF CDX2 CTNNB1 EGFR KRAS MUC2
4 lynch syndrome 29.2 BRAF CD274 CTNNB1 KRAS MUC2
5 cap polyposis 10.8 MUC2 MUC5AC
6 anus adenocarcinoma 10.8 CDX2 MUC5AC
7 malignant peritoneal mesothelioma 10.8 EGFR MUC1
8 mucinous ovarian cystadenoma 10.8 CDX2 MUC1 MUC5AC
9 apocrine adenoma 10.8 KRAS MUC1
10 hepatoid adenocarcinoma 10.8 CDX2 EGFR MUC1
11 bile duct mucoepidermoid carcinoma 10.7 MUC1 MUC2 MUC5AC
12 polyposis, skin pigmentation, alopecia, and fingernail changes 10.7 CDX2 MUC2 MUC5AC
13 ampulla of vater adenocarcinoma 10.7 CDX2 MUC1 MUC2
14 meconium ileus 10.7 MUC1 MUC2 MUC5AC
15 pancreatic mucinous cystadenoma 10.7 MUC1 MUC2 MUC5AC
16 clear cell adenoma 10.7 CTNNB1 MUC2 MUC5AC
17 papillary tumor of the pineal region 10.7 BRAF MUC1
18 secretory meningioma 10.7 CDX2 MUC1 MUC2
19 pancreatic intraductal papillary-mucinous neoplasm 10.6 MUC1 MUC2 MUC6
20 syringocystadenoma papilliferum 10.6 BRAF KRAS MUC1
21 tumor of exocrine pancreas 10.6 MUC1 MUC2 MUC6
22 adenomyoma 10.6 CTNNB1 MUC1 MUC6
23 bronchiolo-alveolar adenocarcinoma 10.6 CDX2 EGFR KRAS
24 tn polyagglutination syndrome 10.6 MUC1 MUC2 MUC6
25 paronychia 10.6 EGFR KRAS
26 mucinous tubular and spindle renal cell carcinoma 10.6 MUC1 MUC2 MUC6
27 hyperplastic polyposis syndrome 10.6 BRAF KRAS
28 cystic teratoma 10.6 CDX2 MUC2 MUC6
29 colonic benign neoplasm 10.6 BRAF CTNNB1 KRAS
30 cystadenoma 10.6 MUC1 MUC2 MUC6
31 microcystic adenoma 10.6 MUC1 MUC6
32 pancreatic ductal carcinoma 10.6 MUC1 MUC2 MUC6
33 papillary craniopharyngioma 10.6 BRAF CTNNB1
34 cholecystitis 10.6 MUC1 MUC2 MUC6
35 differentiated thyroid carcinoma 10.5 BRAF EGFR KRAS
36 cystitis cystica 10.5 CDX2 CTNNB1 MUC2 MUC5AC
37 cell type benign neoplasm 10.5 CTNNB1 KRAS MUC2
38 bile duct carcinoma 10.5 CDX2 EGFR MUC1 MUC2
39 chronic ethmoiditis 10.5 MUC1 MUC2 MUC5AC MUC6
40 bile duct cystadenocarcinoma 10.5 MUC1 MUC2 MUC5AC MUC6
41 atypical polypoid adenomyoma 10.5 CTNNB1 MUC6
42 mucinous intrahepatic cholangiocarcinoma 10.4 CDX2 MUC2 MUC5AC MUC6
43 ethmoid sinusitis 10.4 MUC1 MUC2 MUC5AC MUC6
44 villous adenoma 10.4 BRAF CDX2 KRAS MUC1
45 superior mesenteric artery syndrome 10.4 CDX2 MUC2 MUC5AC MUC6
46 colorectal cancer 1 10.4 MUC1 MUC2 MUC5AC MUC6
47 ovarian mucinous neoplasm 10.4 CDX2 MUC2 MUC5AC MUC6
48 colloid carcinoma of the pancreas 10.4 KRAS MUC1 MUC2 MUC5AC
49 bile duct adenocarcinoma 10.4 KRAS MUC1 MUC2 MUC5AC
50 appendix cancer 10.4 CDX2 KRAS MUC1 MUC2

Graphical network of the top 20 diseases related to Small Intestinal Adenocarcinoma:



Diseases related to Small Intestinal Adenocarcinoma

Symptoms & Phenotypes for Small Intestinal Adenocarcinoma

GenomeRNAi Phenotypes related to Small Intestinal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.91 BRAF EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 9.91 KRAS
3 Decreased viability GR00221-A-1 9.91 EGFR KRAS
4 Decreased viability GR00221-A-2 9.91 KRAS
5 Decreased viability GR00221-A-4 9.91 BRAF EGFR
6 Decreased viability GR00301-A 9.91 BRAF KRAS
7 Decreased viability GR00381-A-1 9.91 BRAF KRAS
8 Decreased viability GR00402-S-2 9.91 MUC1 BRAF EGFR KRAS
9 Decreased cell migration GR00055-A-1 9.65 BRAF CTNNB1 EGFR KRAS MUC1
10 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CD44 CTNNB1 EGFR ERBB2 MUC1
11 Increased cell migration GR00055-A-3 8.92 BRAF CTNNB1 EGFR KRAS

MGI Mouse Phenotypes related to Small Intestinal Adenocarcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 MUC2 PDCD1 PROM1 ALDH1A1 BAX BCL2L2
2 homeostasis/metabolism MP:0005376 10.39 BAX BCL2L2 BRAF CD274 CD44 CDX2
3 growth/size/body region MP:0005378 10.37 ALDH1A1 BAX BCL2L2 BRAF CD44 CDX2
4 endocrine/exocrine gland MP:0005379 10.35 ALDH1A1 BAX BCL2L2 BRAF CD44 CDX2
5 mortality/aging MP:0010768 10.34 ALDH1A1 BAX BRAF CD274 CD44 CDX2
6 behavior/neurological MP:0005386 10.3 BRAF CD274 CD44 CTNNB1 ERBB2 KRAS
7 cardiovascular system MP:0005385 10.29 CDX2 CTNNB1 EGFR ERBB2 KRAS MUC2
8 immune system MP:0005387 10.24 BAX BRAF CD274 CD44 CTNNB1 EGFR
9 digestive/alimentary MP:0005381 10.23 MUC5AC BRAF CD44 CDX2 CTNNB1 EGFR
10 neoplasm MP:0002006 10.2 BAX BRAF CD44 CDX2 CTNNB1 EGFR
11 nervous system MP:0003631 10.17 ALCAM BAX BCL2L2 BRAF CD44 CTNNB1
12 muscle MP:0005369 10.08 BAX BRAF CD44 CTNNB1 EGFR ERBB2
13 limbs/digits/tail MP:0005371 10.07 BAX CD44 CDX2 CTNNB1 EGFR ERBB2
14 normal MP:0002873 10.06 ALDH1A1 BRAF CD44 CDX2 CTNNB1 EGFR
15 liver/biliary system MP:0005370 10.05 ALDH1A1 BRAF CD44 CTNNB1 EGFR KRAS
16 reproductive system MP:0005389 9.91 EGFR ERBB2 KRAS BRAF CD44 CDX2
17 renal/urinary system MP:0005367 9.87 BAX BRAF CD44 CTNNB1 EGFR KRAS
18 respiratory system MP:0005388 9.81 ALDH1A1 BAX BRAF CD44 CTNNB1 EGFR
19 pigmentation MP:0001186 9.77 BRAF CTNNB1 EGFR KRAS PROM1
20 skeleton MP:0005390 9.65 BAX BRAF CD274 CD44 CDX2 CTNNB1
21 vision/eye MP:0005391 9.36 EGFR KRAS MUC5AC PDCD1 PROM1 ALCAM

Drugs & Therapeutics for Small Intestinal Adenocarcinoma

Drugs for Small Intestinal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
9 Dexamethasone acetate Phase 3 1177-87-3
10 Analgesics Phase 3
11 glucocorticoids Phase 3
12
protease inhibitors Phase 3
13 Central Nervous System Depressants Phase 3
14 Adjuvants, Anesthesia Phase 3
15 Serotonin Agents Phase 3
16 Serotonin Antagonists Phase 3
17 Gastrointestinal Agents Phase 3,Phase 2
18 Narcotics Phase 3
19 Neurotransmitter Agents Phase 3
20 Analgesics, Opioid Phase 3
21 HIV Protease Inhibitors Phase 3
22 Anesthetics Phase 3
23 Hormone Antagonists Phase 3
24 Anesthetics, General Phase 3
25 Dermatologic Agents Phase 3,Not Applicable
26 Anesthetics, Intravenous Phase 3
27 Tranquilizing Agents Phase 3
28 Hormones Phase 3
29 Anti-Anxiety Agents Phase 3
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
31 Peripheral Nervous System Agents Phase 3
32 Antiemetics Phase 3
33 Anti-Inflammatory Agents Phase 3
34 Antipruritics Phase 3
35 Antipsychotic Agents Phase 3
36 Psychotropic Drugs Phase 3
37 BB 1101 Phase 3
38 Autonomic Agents Phase 3
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Hydroxyurea Approved Phase 2 127-07-1 3657
44
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
45
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
46
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
47
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
48
Melphalan Approved Phase 2 148-82-3 4053 460612
49
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
50
Floxuridine Approved Phase 2,Phase 1 50-91-9 5790

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
5 Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
6 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
7 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
8 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
9 Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
10 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
11 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
12 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
13 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
14 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
15 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
16 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Recruiting NCT02949219 Phase 2
17 Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting NCT03108131 Phase 2 Cobimetinib;Atezolizumab
18 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
19 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
20 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Active, not recruiting NCT01202409 Phase 2 Panitumumab
21 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
22 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Unknown status NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
23 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
24 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
25 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
26 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
27 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
28 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
29 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
30 Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer Completed NCT00003439 Phase 1
31 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
32 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
33 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
34 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
35 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1
36 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
37 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
38 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
39 Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma Recruiting NCT03000179 Phase 1 Avelumab
40 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting NCT03095781 Phase 1 XL888
41 Enteroscopy for Early Diagnosis of Tumors in Celiac Disease Unknown status NCT02325232 Not Applicable
42 Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder Completed NCT00489515
43 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
44 Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease Recruiting NCT03095573 Not Applicable
45 Phenotyping of Small Bowel Adenocarcinoma Active, not recruiting NCT02976090
46 EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer Terminated NCT00087191 Not Applicable EF5;motexafin lutetium

Search NIH Clinical Center for Small Intestinal Adenocarcinoma

Genetic Tests for Small Intestinal Adenocarcinoma

Anatomical Context for Small Intestinal Adenocarcinoma

MalaCards organs/tissues related to Small Intestinal Adenocarcinoma:

41
Small Intestine, Breast, Lung, Liver, Appendix, Pancreas, Colon

Publications for Small Intestinal Adenocarcinoma

Articles related to Small Intestinal Adenocarcinoma:

(show all 37)
# Title Authors Year
1
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? ( 28821192 )
2017
2
Lynch syndrome-related small intestinal adenocarcinomas. ( 28206961 )
2017
3
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. ( 26892442 )
2016
4
Correlation of Musashi-1, Lgr5, and pEGFR expressions in human small intestinal adenocarcinomas. ( 25773390 )
2015
5
SMALL INTESTINAL ADENOCARCINOMA WITH CARCINOMATOSIS IN A SWIFT FOX (VULPES VELOX). ( 26352968 )
2015
6
Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis. ( 25736860 )
2015
7
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. ( 25710579 )
2015
8
Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. ( 24603585 )
2014
9
Notch3 signaling is associated with MUC5AC expression and favorable prognosis in patients with small intestinal adenocarcinomas. ( 24810798 )
2014
10
Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology. ( 24240591 )
2013
11
Molecular alterations of EGFR in small intestinal adenocarcinoma. ( 23644682 )
2013
12
Small intestinal adenocarcinoma: rarely considered, often missed? ( 23412393 )
2013
13
Combined loss of E-cadherin and aberrant I^-catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas. ( 23355201 )
2013
14
Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. ( 24018801 )
2013
15
S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. ( 24062356 )
2013
16
[Expression of Bcl-w protein in human small intestinal adenocarcinoma and effect of Bcl-w siRNA on apoptosis in intestinal adenocarcinoma HuTu-80 cells]. ( 22780970 )
2012
17
Surgical versus non-surgical treatment of feline small intestinal adenocarcinoma and the influence of metastasis on long-term survival in 18 cats (2000-2007). ( 22467965 )
2011
18
Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. ( 22966319 )
2010
19
Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation. ( 19852062 )
2010
20
Small intestinal adenocarcinoma in common marmosets (Callithrix jacchus). ( 20460447 )
2010
21
Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. ( 21088150 )
2010
22
Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. ( 19926579 )
2009
23
Significance of increased apoptosis and Bax expression in human small intestinal adenocarcinoma. ( 19729672 )
2009
24
Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse. ( 18182527 )
2008
25
Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. ( 17951204 )
2007
26
Adjuvant chemotherapy for small intestine adenocarcinoma. ( 17636789 )
2007
27
Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. ( 16501564 )
2006
28
Small intestinal adenocarcinoma in Peutz-Jeghers syndrome. ( 16567896 )
2006
29
Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel. ( 16619216 )
2006
30
Loss of SMAD4 function in small intestinal adenocarcinomas: comparison of genetic and immunohistochemical findings. ( 15157044 )
2004
31
Small intestinal adenocarcinoma in Crohn's disease: a case-control study. ( 15058524 )
2004
32
Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. ( 15513360 )
2004
33
Mucinous adenocarcinoma of the small bowel with peritoneal seeding. ( 11869008 )
2002
34
[Crohn's disease and small intestine adenocarcinoma]. ( 11534361 )
2001
35
Adenocarcinoma of the small bowel, coeliac disease, and lymphocytic gastritis. ( 10193339 )
1998
36
Caecal adenocarcinoma with multiple synchronous small intestinal adenocarcinoma. ( 9519189 )
1997
37
Electron microscopic study of adenocarcinoma of the small bowel associated with Crohn's disease. ( 6840256 )
1983

Variations for Small Intestinal Adenocarcinoma

Cosmic variations for Small Intestinal Adenocarcinoma:

9
(show top 50) (show all 564)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6971229 ZRSR2 small intestine,duodenum,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 20
2 COSM6973250 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 20
3 COSM6845179 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 20
4 COSM6913839 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.538G>T p.D180Y 11:32428524-32428524 20
5 COSM1130534 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 20
6 COSM6917759 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 20
7 COSM6968949 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
8 COSM11090 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.541C>T p.R181C 17:7675071-7675071 20
9 COSM10659 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.817C>T p.R273C 17:7673803-7673803 20
10 COSM10662 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 20
11 COSM43970 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.380C>A p.S127Y 17:7675232-7675232 20
12 COSM10738 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 20
13 COSM6932 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.733G>A p.G245S 17:7674230-7674230 20
14 COSM43545 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 20
15 COSM10724 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.839G>C p.R280T 17:7673781-7673781 20
16 COSM10663 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 20
17 COSM10758 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.659A>G p.Y220C 17:7674872-7674872 20
18 COSM10788 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.764T>G p.I255S 17:7674199-7674199 20
19 COSM43606 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.734G>A p.G245D 17:7674229-7674229 20
20 COSM10739 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.481G>A p.A161T 17:7675131-7675131 20
21 COSM10867 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.797G>A p.G266E 17:7673823-7673823 20
22 COSM10654 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 20
23 COSM10768 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.535C>T p.H179Y 17:7675077-7675077 20
24 COSM43714 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.836G>A p.G279E 17:7673784-7673784 20
25 COSM43829 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.752T>G p.I251S 17:7674211-7674211 20
26 COSM44393 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.821T>C p.V274A 17:7673799-7673799 20
27 COSM11089 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.584T>C p.I195T 17:7674947-7674947 20
28 COSM43555 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.736A>G p.M246V 17:7674227-7674227 20
29 COSM10704 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 20
30 COSM10648 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 20
31 COSM5731186 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.1052A>G p.K351R 17:7670657-7670657 20
32 COSM44218 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.536A>C p.H179P 17:7675076-7675076 20
33 COSM4116810 TGFBR2 small intestine,jejunum,carcinoma,adenocarcinoma c.1277C>T p.A426V 3:30674127-30674127 20
34 COSM6961805 TGFBR1 small intestine,duodenum,carcinoma,adenocarcinoma c.1124C>A p.T375K 9:99144882-99144882 20
35 COSM6968905 TET2 small intestine,duodenum,carcinoma,adenocarcinoma c.1124A>G p.E375G 4:105235066-105235066 20
36 COSM6973233 TENT5C small intestine,jejunum,carcinoma,adenocarcinoma c.839A>G p.D280G 1:117623707-117623707 20
37 COSM6971222 SUZ12 small intestine,duodenum,carcinoma,adenocarcinoma c.1058C>A p.P353H 17:31988354-31988354 20
38 COSM6973254 STK11 small intestine,jejunum,carcinoma,adenocarcinoma c.719C>T p.S240L 19:1220702-1220702 20
39 COSM25847 STK11 small intestine,duodenum,carcinoma,adenocarcinoma c.580G>A p.D194N 19:1220488-1220488 20
40 COSM6968955 STAT3 small intestine,duodenum,carcinoma,adenocarcinoma c.635A>G p.Q212R 17:42337773-42337773 20
41 COSM6946712 STAG2 small intestine,duodenum,carcinoma,adenocarcinoma c.3018T>G p.F1006L 23:124083514-124083514 20
42 COSM1227526 SRC small intestine,duodenum,carcinoma,adenocarcinoma c.1460C>T p.P487L 20:37403228-37403228 20
43 COSM2087949 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.4586G>A p.R1529H 1:15930826-15930826 20
44 COSM6968895 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.617G>A p.R206H 1:15876414-15876414 20
45 COSM6959363 SOX9 small intestine,duodenum,carcinoma,adenocarcinoma c.242T>C p.L81P 17:72121633-72121633 20
46 COSM6919014 SOX9 small intestine,duodenum,carcinoma,adenocarcinoma c.934C>T p.Q312* 17:72123791-72123791 20
47 COSM6968916 SMO small intestine,duodenum,carcinoma,adenocarcinoma c.1571C>T p.A524V 7:129210467-129210467 20
48 COSM6971224 SMARCA4 small intestine,duodenum,carcinoma,adenocarcinoma c.2647G>T p.G883C 19:11021755-11021755 20
49 COSM14122 SMAD4 small intestine,jejunum,carcinoma,adenocarcinoma c.1082G>A p.R361H 18:51065549-51065549 20
50 COSM14163 SMAD4 small intestine,jejunum,carcinoma,adenocarcinoma c.931C>T p.Q311* 18:51059892-51059892 20

Copy number variations for Small Intestinal Adenocarcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13776 1 1 39600000 Copy number LCK Small bowel adenocarcinoma
2 13777 1 1 39600000 Copy number MDS2 Small bowel adenocarcinoma
3 13778 1 1 39600000 Copy number PAX7 Small bowel adenocarcinoma
4 13779 1 1 39600000 Copy number PRDM16 Small bowel adenocarcinoma
5 13780 1 1 39600000 Copy number RPL22 Small bowel adenocarcinoma
6 13781 1 1 39600000 Copy number SDHB Small bowel adenocarcinoma
7 76578 13 32900000 93800000 Copy number LCP1 Small bowel adenocarcinoma
8 76579 13 32900000 93800000 Copy number LHFP Small bowel adenocarcinoma
9 76580 13 32900000 93800000 Copy number RB1 Small bowel adenocarcinoma
10 106872 17 1 6800000 Copy number USP6 Small bowel adenocarcinoma
11 180663 4 10900000 191273063 Copy number CHIC2 Small bowel adenocarcinoma
12 180664 4 10900000 191273063 Copy number FBXW7 Small bowel adenocarcinoma
13 180665 4 10900000 191273063 Copy number FIP1L1 Small bowel adenocarcinoma
14 180666 4 10900000 191273063 Copy number IL2 Small bowel adenocarcinoma
15 180667 4 10900000 191273063 Copy number KIT Small bowel adenocarcinoma
16 180668 4 10900000 191273063 Copy number PDGFRA Small bowel adenocarcinoma
17 180669 4 10900000 191273063 Copy number PHOX2B Small bowel adenocarcinoma
18 180670 4 10900000 191273063 Copy number RAP1GDS1 Small bowel adenocarcinoma
19 244962 9 1 51800000 Copy number FANCG Small bowel adenocarcinoma
20 244963 9 1 51800000 Copy number JAK2 Small bowel adenocarcinoma
21 244964 9 1 51800000 Copy number MLLT3 Small bowel adenocarcinoma
22 244965 9 1 51800000 Copy number PAX5 Small bowel adenocarcinoma

Expression for Small Intestinal Adenocarcinoma

Search GEO for disease gene expression data for Small Intestinal Adenocarcinoma.

Pathways for Small Intestinal Adenocarcinoma

Pathways related to Small Intestinal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 BRAF CD274 CD44 CTNNB1 EGFR ERBB2
2
Show member pathways
13.66 BRAF CTNNB1 EGFR ERBB2 KRAS MUC1
3
Show member pathways
12.83 BRAF CTNNB1 EGFR ERBB2 KRAS
4
Show member pathways
12.79 BAX BRAF CTNNB1 EGFR ERBB2 KRAS
5 12.75 BAX BRAF CTNNB1 EGFR ERBB2 KRAS
6
Show member pathways
12.71 BAX BRAF EGFR ERBB2 KRAS
7
Show member pathways
12.65 BAX BRAF CTNNB1 ERBB2 KRAS
8
Show member pathways
12.53 BAX CTNNB1 EGFR ERBB2 KRAS
9
Show member pathways
12.43 BRAF EGFR ERBB2 KRAS
10 12.43 BCL2L2 CD44 EGFR ERBB2 KRAS
11
Show member pathways
12.41 BRAF EGFR ERBB2 KRAS
12
Show member pathways
12.34 BRAF CD44 CTNNB1 KRAS
13
Show member pathways
12.33 BAX CTNNB1 EGFR ERBB2 KRAS
14
Show member pathways
12.28 BRAF CTNNB1 EGFR ERBB2 KRAS MUC1
15
Show member pathways
12.27 KRAS MUC1 MUC2 MUC5AC MUC6
16
Show member pathways
12.22 BAX BRAF CDX2 CTNNB1 EGFR ERBB2
17
Show member pathways
12.17 MUC1 MUC2 MUC5AC MUC6
18 12.12 BRAF EGFR ERBB2 KRAS
19 12.09 BAX EGFR ERBB2 KRAS
20
Show member pathways
12.05 MUC1 MUC2 MUC5AC MUC6
21 11.98 BAX BRAF CTNNB1 EGFR KRAS
22 11.94 BRAF CD44 CTNNB1 EGFR ERBB2 KRAS
23
Show member pathways
11.92 BRAF EGFR ERBB2 KRAS
24 11.9 BAX CTNNB1 ERBB2 KRAS
25 11.87 BRAF CTNNB1 EGFR KRAS
26 11.84 BAX BRAF CTNNB1 EGFR KRAS
27
Show member pathways
11.83 MUC1 MUC2 MUC5AC MUC6
28
Show member pathways
11.75 BAX BRAF KRAS
29 11.68 CTNNB1 EGFR ERBB2
30 11.64 CTNNB1 EGFR ERBB2
31 11.62 EGFR ERBB2 KRAS
32 11.57 BRAF EGFR ERBB2 KRAS
33 11.54 EGFR ERBB2 KRAS
34 11.39 BRAF EGFR KRAS
35 11.08 BRAF EGFR KRAS
36 10.5 CTNNB1 EGFR ERBB2 KRAS PROM1

GO Terms for Small Intestinal Adenocarcinoma

Cellular components related to Small Intestinal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 focal adhesion GO:0005925 9.72 ALCAM CD44 CTNNB1 EGFR KRAS
2 apical plasma membrane GO:0016324 9.55 CD44 EGFR ERBB2 MUC1 PROM1
3 plasma membrane GO:0005886 9.47 ALCAM BRAF CD274 CD44 CTNNB1 EGFR
4 Bcl-2 family protein complex GO:0097136 9.26 BAX BCL2L2
5 Golgi lumen GO:0005796 9.26 MUC1 MUC2 MUC5AC MUC6
6 extracellular exosome GO:0070062 10.07 ALCAM ALDH1A1 BAX BCL2L2 CD274 CD44

Biological processes related to Small Intestinal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.85 BRAF EGFR ERBB2 KRAS
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.78 BRAF CD44 EGFR ERBB2
3 liver development GO:0001889 9.69 CPS1 EGFR KRAS
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 BRAF CD44 EGFR
5 negative regulation of apoptotic process GO:0043066 9.63 BCL2L2 BRAF CD44 EGFR ERBB2 PDCD1
6 positive regulation of kinase activity GO:0033674 9.61 CD44 EGFR ERBB2
7 positive regulation of MAP kinase activity GO:0043406 9.58 EGFR ERBB2 KRAS
8 epithelial tube branching involved in lung morphogenesis GO:0060441 9.57 CTNNB1 KRAS
9 negative regulation of ERBB signaling pathway GO:1901185 9.56 EGFR ERBB2
10 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902166 9.54 CD44 MUC1
11 cellular response to growth factor stimulus GO:0071363 9.54 CTNNB1 EGFR ERBB2
12 maintenance of gastrointestinal epithelium GO:0030277 9.52 MUC2 MUC6
13 midgut development GO:0007494 9.46 CPS1 EGFR
14 ERBB2 signaling pathway GO:0038128 9.43 EGFR ERBB2 KRAS
15 Sertoli cell proliferation GO:0060011 9.32 BAX BCL2L2
16 O-glycan processing GO:0016266 9.26 MUC1 MUC2 MUC5AC MUC6
17 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 KRAS MUC1 MUC2 MUC5AC MUC6

Molecular functions related to Small Intestinal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAP kinase kinase kinase activity GO:0004709 9.58 BRAF EGFR ERBB2
2 protein phosphatase binding GO:0019903 9.5 CTNNB1 EGFR ERBB2
3 mitogen-activated protein kinase kinase binding GO:0031434 9.43 BRAF EGFR ERBB2
4 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.37 EGFR ERBB2
5 nucleotide binding GO:0000166 9.35 BRAF CPS1 EGFR ERBB2 KRAS
6 protein heterodimerization activity GO:0046982 9.1 BAX BCL2L2 BRAF CTNNB1 EGFR ERBB2
7 protein binding GO:0005515 10.09 ALCAM BAX BCL2L2 BRAF CD274 CD44

Sources for Small Intestinal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....